Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia

Journal of Urology

Volumn 172, Issue 4 I, 2004, Pages 1399-1403

  Andriole, Gerald ^a,h   Bruchovsky, Nicholas ^b   Chung, Leland W K ^c   Matsumoto, Alvin M ^d   Rittmaster, Roger ^e   Roehrborn, Claus ^f   Russell, David ^f   Tindall, Donald ^g  

^a WASHINGTON UNIVERSITY   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g Mayo Clinic   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dihydrotestosterone; Finasteride; GG 745; Prostate; Prostatic hyperplasia

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADAPTATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; LITERATURE; MEDLINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; SYMPTOM; URINE FLOW RATE; URINE RETENTION;

EID: 4544285381     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000139539.94828.29     Document Type: Article

References (20)

1. Wilson, J. D.: The role of 5α-reduction in steroid hormone physiology. Reprod Fertil Dev, 13: 673, 2001
2. Iehle, C., Radvanyi, F., Gil Diez de Medina, S., Ouafik, L. H., Gerard, H., Chopin, D. et al: Differences in steroid 5alpha-reductase iso-enzyme expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol, 68: 189, 1999
3. Berthaut, I., Mestayer, C., Portois, M. C., Cussenot, O. and Mowszowicz, I.: Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture. Prostate, 32: 155, 1997
4. Bruchovsky, N., Rennie, P. S., Batzold, F. H., Goldenberg, S. L., Fletcher, T. and McLoughlin, M. G.: Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. J Clin Endocrinol Metab, 67: 806, 1988
5. Bruchovsky, N., Sadar, M. D., Akakura, K., Goldenberg, S. L., Matsuoka, K. and Rennie, P. S.: Characterization of 5 alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol, 59: 397, 1996
6. Thomas, L. N., Douglas, R. C., Vessey, J. P., Gupta, R., Fontaine, D., Norman, R. W. et al: 5α-Reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol, 170: 2019, 2003
7. Habib, F. K., Ross, M., Bayne, C. W., Bollina, P., Grigor, K. and Chapman, K.: The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clin Cancer Res, 9: 1815, 2003
8. Wright, A. S., Douglas, R. C., Thomas, L. N., Lazier, C. B. and Rittmaster, R. S.: Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology, 140: 4509, 1999
9. Wilson, J. D.: Androgens. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. Edited by J. G. Hardman and L. E. Limbird. New York: McGraw-Hill, chapt. 58, pp. 1441-1458, 1996
10. Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G. et al: The influence of finasteride on the development of prostate cancer. N Engl J Med, 349: 215, 2003
11. Abu, E. O., Horner, A., Kusec, V., Triffitt, J. T. and Compston, J. E.: The localization of androgen receptors in human bone. J Clin Endocrinol Metab, 82: 3493, 1997
12. Arisaka, O., Arisaka, M., Nakayama, Y., Fujiwara, S. and Yabuta, K.: Effect of testosterone on bone density and bone metabolism in adolescent male hypogonadism. Metabolism, 44: 419, 1995
13. Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M. et al: Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab, 89: 503, 2004
14. Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., Andriole, G. and the ARIA3001 ARIA3002 and ARIA3003 Study Investigators: Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 60: 434, 2002
15. McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L. et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med, 338: 557, 1998
16. Pareek, G., Shevchuk, M., Armenakas, N. A., Vasjovic, L., Hochberg, D. A., Basillote, J. B. et al: The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol, 169: 20, 2003
17. Andriole, G. L. and Kirby, R.: Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol, 44: 82, 2003
18. Overstreet, J. W., Fuh, V. L., Gould, J., Howards, S. S., Lieber, M. M., Hellstrom, W. et al: Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol, 162: 1295, 1999
19. Matsumoto, A. M., Tenover, L., McClung, M., Mobley, D., Geller, J., Sullivan, M. et al: The long-term effect of specific type II 5α-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo-controlled trial. J Urol, 167: 2105, 2002
20. Clark, R. V., Huffman, C. S., Swerdloff, R. S., Wang, C., Matsumoto, A. and Bremner, W.: Potent DHT suppression by the novel dual 5α-reductase inhibitor dutasteride does not affect bone density, bone metabolism or lipid profiles in healthy men. Presented at XVIIIth Congress of European Association of Urology, Madrid, Spain, March 12-15, 2003